|
11 Dec 2019 |
AffaMed Therapeutics Receives NMPA Approval to Initiate Phase III Clinical Trial in China with Herceptin® (Trastuzumab) Biosimilar Candidate AMT901
|
|
11 Dec 2019 |
Positive results presented from pivotal Phase 3 trial of sutimlimab in people with cold agglutinin disease
|
|
11 Dec 2019 |
Iterum Therapeutics Announces Topline Results from Phase 3 Clinical Trial of Oral and IV Sulopenem for the Treatment of Complicated Intra-abdominal Infections
|
|
11 Dec 2019 |
Regeneron and Sanofi Announce Intent to Restructure Antibody Collaboration for Kevzara® (sarilumab) and Praluent® (alirocumab)
|
|
11 Dec 2019 |
Darzalex (daratumumab) Regimen Shows Significant Increase in Progression-Free Survival in Treatment of Patients with Relapsed/Refractory Multiple Myeloma
|
|
11 Dec 2019 |
LEO Pharma announces positive top-line results for tralokinumab from three Phase 3 studies in adult patients with moderate-to-severe AD
|
|
11 Dec 2019 |
BioInvent and Transgene announce compelling preclinical data for BT-001 in solid tumors
|
|
11 Dec 2019 |
FDA Accepts Supplemental Biologics License Application for Xolair (Omalizumab) for the Treatment of Nasal Polyps
|
|
11 Dec 2019 |
First patient dosed in BIVV001 phase 3 XTEND-1 study in people with severe haemophilia A
|
|
10 Dec 2019 |
ADC Therapeutics Announces Oral Presentation of Interim Efficacy Data from Pivotal Phase 2 Clinical Trial of ADCT-402 (Loncastuximab Tesirine) in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma at 61st ASH Annual Meeting
|
|
10 Dec 2019 |
Forty Seven, Inc. Announces Foundational Preclinical Data Supporting the Development of FSI-174 in Combination with Magrolimab as a Novel All Antibody Conditioning Regimen for Hematopoietic Stem Cell Transplantation
|
|
10 Dec 2019 |
MacroGenics Presents Flotetuzumab Data in Patients with Primary Induction Failure and Early Relapsed Acute Myeloid Leukemia at the 2019 ASH Annual Meeting
|
|
10 Dec 2019 |
CARsgen Therapeutics Receives IND Clearance from the NMPA for AB011 Humanized Claudin18.2 Monoclonal Antibody
|
|
10 Dec 2019 |
CStone's anti-PD-L1 antibody demonstrates promising antitumor activity with a complete response rate of 33.3% and a good safety profile in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma
|
|
10 Dec 2019 |
ImmunoGen Presents Updated Findings from Phase 1 Study of IMGN632 at ASH Annual Meeting
|
|
10 Dec 2019 |
Amphivena Reports Data on Phase 1 Study of AMV564 at Ash Annual Meeting
|
|
10 Dec 2019 |
UCB Presents Final Results from Phase II Study of Rozanolixizumab in Primary Immune Thrombocytopenia (ITP) at 2019 ASH Annual Meeting
|
|
09 Dec 2019 |
Xencor Presents Initial Data from Phase 1 Study of XmAb®13676 in B-cell Malignancies at the ASH Annual Meeting
|
|
09 Dec 2019 |
Magenta Therapeutics Demonstrates First-ever Successful Gene Therapy Transplant Without Chemotherapy in Primates Using a Single Dose of Antibody-drug Conjugate
|
|
09 Dec 2019 |
Alpine Immune Sciences Presents ALPN-101 Phase 1 Healthy Volunteer Study Data and Details of Upcoming Phase I/II BALANCE GVHD Study at the 61st American Society of Hematology Annual Meeting
|
|
09 Dec 2019 |
IONTAS Antibody Enters Clinical Trial for Use in the Treatment of B Cell Acute Lymphoblastic Leukemia
|
|
09 Dec 2019 |
Sesen Bio Initiates Rolling Submission of BLA for Vicinium to FDA
|
|
09 Dec 2019 |
First Clinical Data for REGN5458 (BCMAxCD3) Show Positive Preliminary Results in Multiple Myeloma
|
|
09 Dec 2019 |
Galderma Investigational Therapy Nemolizumab Granted FDA Breakthrough Therapy Designation for the Treatment of Patients Suffering from Prurigo Nodularis
|
|
09 Dec 2019 |
Immunocore announces dosing of first patient with third ImmTAC® bispecific
|
